Lopinavir/Ritonavir (Kaletra) PK in Children

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
HIV/AIDS TreatmentHIV Infections
Interventions
DRUG

lopinavir/ritonavir (Kaletra®) tablets

The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).

Trial Locations (2)

20010

Children's National Medical Center, Washington D.C.

92103

University of California, San Diego - Skaggs School of Pharmacy and School of Medicine, San Diego

All Listed Sponsors
collaborator

American Association of Colleges of Pharmacy

OTHER

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00810108 - Lopinavir/Ritonavir (Kaletra) PK in Children | Biotech Hunter | Biotech Hunter